Endocrine Abstracts

Introduction: Thyroid nodules can be detected by ultrasound (US) in 20–30% of unselected populations. Various non-surgical techniques such as laser and radiofrequency ablation have been developed to reduce thyroid nodule size. High-intensity focused ultrasound (HIFU) ablation is a new, non-invasive method that has been shown recently. The aim of our study was to assess the long-term efficacy and safety of US-guided HIFU treatment of benign solid thyroid nodules.<p cla...

Background: Thyroid nodule is the most common endocrine disorder with the prevalence of more than 50% in adults. Majority of nodules are small in size and can be detected only by various imaging methods. Thyroid nodules are usually benign, asymptomatic, and do not need treatment. Growing and large symptomatic thyroid nodules are usually treated with thyroidectomy. Novel minimally invasive ablation techniques can be alternative to surgery. Percutaneous laser ablation is causing...

Background: GLP-1 agonism have the potential to affect gastric emptying (GE), yet the reports for subcutaneous semaglutide, currently the most effective GLP-1 RA approved for weight management, remain inconclusive. It has been demonstrated that semaglutide either had no effect on GE or it delayed GE only within the first hour, without late phase retention. Notably, those conclusions were made by an indirect method of estimation of GE through ingestion, absorption and determina...

Objectives: Overt hyperthyroidism is reported to be associated with an increased mortality risk and an increased risk of cardiovascular (CV) complications such as an acute coronary syndrome requiring percutaneous coronary intervention, ischemic and non-ischemic stroke, atrial fibrillation and venous thromboembolism. Increased rate of acute CV events in the course of hyperthyroidism is well documented in Graves’ disease (GD) but not in subacute thyroiditis (ST). Last year ...

Introduction: The prevalence of thyroid nodules detected by ultrasound (US) is up to 50% in general population and approximately 5−10% of them is malignant. Diagnostic assessment includes laboratory tests thyroid US and thyroid scintigraphy, where suspicious nodules are characteristically cold when using99m Tc-pertechnetate as a tracer. A useful tool for US-based risk stratification of thyroid nodules is Thyroid Imaging Reporting and Data System (TIRADS). Rece...

Introduction: Radioiodine (I-131) therapy is an effective treatment for thyroid autonomy but may induce Graves’ disease (GD) but in up to 5% of patients. GD is characterised by antibodies against TSH receptor (TSHRAb). We set out to evaluate the incidence and risk factors of I-131-induced GD in patients with thyroid autonomy treated with I-131.Methods: We retrospectively reviewed patients with solitary toxic adenoma or toxic nodular goiter who were ...

Aim: In Graves’ disease (GD) the goal of radioiodine (I-131) application is the elimination of hyperthyroidism. The reported success rate 1 year after treatment is up to 90%. The aim of this retrospective study was to assess the factors influencing the early outcome 3 months after I-131 treatment of GD patients in an iodine sufficient area.Materials and Methods: We reviewed medical records of GD patients who received I-131 therapy between January 20...

Objectives: Ultrasound-guided fine needle aspiration biopsy (FNAB) is a commonly performed diagnostic procedure for evaluation of thyroid nodules. The Bethesda System for Reporting Thyroid Cytopathology comprises six categories. Bethesda categories I and III present a challenge for deciding on further diagnostic and therapeutic procedures. Category I includes non-diagnostic or unsatisfactory results that may be due to both aspiration of cystic material from simple cysts or asp...

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...